

5/21/2015; Page 1

00	Dehydroepiandrosterone 10 mg Oral Capsules (Powder Blend, 100 x Size #1 Capsules)	FIN	F 003 522v2
----	--	-----	-------------

# SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Dehydroepiandrosterone (Prasterone) (DHEA) (Micronized)	1.000	g				
Medisca CapsuBlend <sup>TM</sup> -P	TBD					
Sodium Chloride, USP	As required					

## SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information		8			
Light sensitive (protect from light whenever possible): Dehydroepiandrosterone					
Hygroscopic (protect from moi	sture whenever possible):	CapsuBlend <sup>™</sup> -P			
Suggested Preparatory Guidelines					
Non-Sterile Preparation Sterile Preparation					
<u>Processing Error /</u> <u>Testing Considerations</u> : To account for processing errors and considerations during preparation, it is suggested to measure an additional <b>5 to 9%</b> of the required quantities of ingredients.					
Special Instruction: Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.					
This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.					



5/21/2015; Page 2

	Dehydroepiandrosterone 10 mg Oral Capsules (Powder Blend, 100 x Size #1 Capsules)	FIN	F 003 522v2	
--	--	-----	-------------	--

### SUGGESTED PREPARATION (for 100 Size #1 Capsules)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor <sup>(*)</sup> :	Processing Error	Qty. to measure
Dehydroepiandrosterone (Prasterone) (DHEA) (Micronized) §	1.000	g			
Medisca CapsuBlend <sup>™</sup> -P §	TBD				
Sodium Chloride, USP	As required	®			

\* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

	Preparatory Instruction
1.	Calculate the quantity of CapsuBlend <sup>TM</sup> -P required for 100 x Size #1 Capsules:
	<ul> <li>A. Determine the average capsule fill weight by filling and weighing five TARED capsules with the CapsuBlend<sup>™</sup>-P. Divide the total weight by 5 to obtain <u>average</u> weight g (A)</li> </ul>
	B. Quantity of CapsuBlend <sup>TM</sup> -P required per capsule = $(A) - 0.010 \text{ g}^*$ *quantity of Dehydroepiandrosterone (Prasterone) (DHEA) (Micronized) per capsule.
	C. Total quantity of CapsuBlend <sup>TM</sup> -P required for the batch = (B) x 100 capsules $g(C)$
	D. Quantity of CapsuBlend <sup>TM</sup> -P to weigh with processing error = (C) x $1.05 \sim 1.09$ g (D)
2.	Powder preparation:
	A. By geometric addition, combine and triturate the following ingredients together:
	-Dehydroepiandrosterone (Prasterone) (DHEA) (Micronized) -CapsuBlend <sup>TM</sup> -P ( <b>D</b> )
	End result: Homogeneous powder blend.
3.	Product transfer:
	Fill each of the 100 Size #1 Capsules with the homogeneous powder blend (Step 3A). Close each capsule tightly.
	Clean each capsule by placing the capsules in a container filled with Sodium Chloride, and then gently rolling the container. Pour the container contents into a 10-mesh sieve, and allow the Sodium Chloride to pass through. Finally, roll the capsules on a cloth-covered surface.



5/21/2015; Page 3

### 4. Validation technique:

The final weight of each capsule (not including capsule shell) should fall between 90 and 110% of the theoretically calculated weight  $(\mathbf{A})$ , in accordance to USP 795 guidelines.

# 5. **Product transfer:**

Transfer the final product into the specified dispensing container (see "Packaging Requirements").

### SUGGESTED PRESENTATION

Estima Beyond-Use D		6 months, as per USP*.	Packaging Requirements		-		Tightly closed, light-resistant capsule shells and vials.
	1	Use as directed. Do not exceed dose.	l prescribed	5	Keep in a dry place.		
	2	Keep out of reach of children.		6	Protect from light.		
Auxiliary Labels	3	Keep at room temperature (20°C	C − 23°C).	7	Cap tightly after use.		
	4	Consult your health care practit other prescription or over medications are currently being prescribed for future use.	-the-counter				
Pharmacist Instructions Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.					ensing container as deemed necessary.		
Patient Instructions	Contact your pharmacist in the event of adverse reactions						

\* The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.



5/21/2015; Page 4

Suggested	Dehydroepiandrosterone 10 mg Oral Capsules (Powder Blend, 100 x Size #1	FIN	F 003 522v2
Formula	Capsules)	1.114	F 003 322v2

### REFERENCES

1.	Capsules. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition.</i> American Pharmaceutical Association; 2008: 127.
2.	Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4<sup>th</sup> Edition</i> . American Pharmaceutical Association; 2003: 556.
3.	Prasterone. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 34<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2005: 1565.
4.	Dehydroepiandrosterone (Monograph). In: O'Neil MJ. <i>The Merck Index 14<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #2871.
5.	USP <795>. United States Pharmacopeia XXXI / National Formulary 26. Rockville, MD. US Pharmacopeial Convention, Inc. 2008.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.